| Name | Title | Contact Details |
|---|
Pavell Jeff Do is a Englewood, NJ-based company in the Business Services sector.
Inxpot is a Dillon, CO-based company in the Business Services sector.
Anzen Automobile Driving Schl is a New York, NY-based company in the Business Services sector.
Springbrook NY, Inc. is a not-for-profit organization based in Oneonta, New York, dedicated to providing comprehensive services for individuals with developmental disabilities. Founded in 1925, it has a strong commitment to fostering an inclusive environment where each person is valued. The organization serves over 1,000 individuals across New York State and beyond, offering tailored support for various age groups. The services provided by Springbrook include self-directed services, educational programs through the GEMS Residential & Day School, and specialized support at the Tom Golisano Center for Autism. They also offer Kids Unlimited Preschool, housing navigation services, employment support, and Capstone Day Habilitation for lifelong learning. Additionally, Springbrook emphasizes physical activity and wellness through various therapeutic supports. With a revenue of approximately $39.8 million and a team of over 451 employees, Springbrook is recognized for its effective use of resources and commitment to transparency, earning a 4/4 Star rating from Charity Navigator.
Denali Therapeutics is a clinical-stage biopharmaceutical company based in South San Francisco, California. The company focuses on developing therapies for neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, as well as lysosomal storage disorders like Hunter syndrome. Denali employs around 422 professionals and utilizes proprietary blood-brain barrier transport technologies to meet the medical needs of patients with brain-related disorders. Denalis innovative approach includes four engineered transport vehicle systems: Enzyme Transport Vehicle (ETV), Antibody Transport Vehicle (ATV), Protein Transport Vehicle (PTV), and Oligonucleotide Transport Vehicle (OTV). These technologies enable the delivery of various therapeutic agents to the brain. The company collaborates with major pharmaceutical partners, including Sanofi, AbbVie, and Takeda, to enhance the development of its pipeline products, which include DNL310 for Hunter syndrome and DNL151 for Parkinson’s disease. Denalis mission is to advance therapies that address the underlying causes of neurodegeneration, emphasizing a commitment to rigorous science and patient-focused innovation.